For a plant long chewed by farmers in Southeast Asia to get through grueling shifts, kratom has become an unlikely flashpoint in Western drug policy debates. As lawmakers in the United States and elsewhere weigh bans and tight restrictions, a growing body of research is quietly painting a more nuanced picture of kratom’s risks and its potential as a harm-reduction tool and therapeutic ally.
That tension between emerging evidence and political reflex is now defining kratom’s future. On one side are headlines about overdose deaths and agency warnings; on the other, an expanding scientific literature suggesting carefully regulated kratom could play a role in pain management and even in easing dependence on more dangerous opioids.
To understand why outright prohibition may be the worst of both worlds, it helps to start with what researchers have actually learned about this complex plant.
Kratom, or Mitragyna speciosa, contains dozens of alkaloids, most notably mitragynine and 7-hydroxymitragynine, that act on some of the same receptors as opioids while also exerting stimulant-like effects at lower doses. The U.S. National Institute on Drug Abuse notes that scientific research on kratom is still relatively new but highlights that federal agencies are now actively funding work on its chemistry, health effects and potential therapeutic uses, including as a treatment for opioid withdrawal and chronic pain, through initiatives such as the NIH HEAL program described on the NIDA kratom information page at nida.nih.gov.
In traditional settings in Malaysia and Thailand, workers have long brewed kratom leaves into tea or chewed them to relieve fatigue, boost mood and alleviate aches. An overview of kratom’s traditional use and pharmacology published in the open-access journal Current Drug Targets and archived on the U.S. National Library of Medicine’s platform at pmc.ncbi.nlm.nih.gov notes that these patterns of use historically coexisted with relatively low levels of documented severe toxicity in local communities, even as daily consumption was common among manual laborers.
In the last decade, Western scientists have begun to test whether these long-standing ethnobotanical claims hold up in controlled conditions. A comprehensive systematic review of preclinical and clinical studies on kratom’s therapeutic potential and safety, published in 2021 and available via the National Center for Biotechnology Information at pmc.ncbi.nlm.nih.gov, examined 57 preclinical and 18 clinical or observational studies. The authors concluded that animal and early human data support possible therapeutic value in acute and chronic pain, mitigation of morphine and ethanol withdrawal, and relief of some mental health–related symptoms, while emphasizing the need for more rigorous trials and standardized products.
Those preliminary benefits are not just theoretical. A 2023 review of clinical implications of kratom use, also hosted in full on the National Library of Medicine’s site at pmc.ncbi.nlm.nih.gov, pointed to a randomized controlled trial in regular kratom users that found enhanced pain tolerance after ingesting their usual kratom brew without significant short-term adverse health effects, underscoring kratom’s analgesic potential when used in familiar, moderate patterns. The same review highlighted observational evidence that some people with histories of heroin or methamphetamine use report turning to kratom to reduce their intake of more dangerous drugs and to manage withdrawal symptoms, suggesting a harm-reduction role that is only beginning to be quantified.
Crucially, these therapeutic hints intersect with a public health crisis that remains acute. With synthetic opioids driving record overdose deaths in countries like the United States, NIDA’s own kratom briefing at nida.nih.gov notes that the institute and its partners are now supporting projects to investigate kratom-derived compounds as potential medications for opioid use disorder. That is a striking shift from a purely prohibitionist stance: the same government that once considered emergency scheduling of kratom is now investing in understanding whether parts of the plant could help treat the very addictions fueling the overdose epidemic.
None of this means kratom is benign. U.S. health agencies have repeatedly signaled concern about unregulated products, adulteration and heavy use. The Food and Drug Administration, which has not approved kratom for any medical use, maintains a health advisory detailing reports of liver toxicity, seizures and substance use disorder in some users, and in 2024 the agency warned that certain branded liquid kratom products were linked to severe illnesses and at least one death, in a notice summarized for clinicians at clinicaladvisor.com. Meanwhile, a 2019 analysis of overdose data from 32 U.S. states found that kratom was listed as a cause of death in nearly 100 cases over 17 months, according to a report cited by the Centers for Disease Control and Prevention and covered by local news outlet WKBW at wkbw.com.
Even those sobering figures, however, demand careful interpretation. In many of the fatalities where kratom was detected, multiple substances were involved, and determining whether kratom was the primary driver or a contributing factor can be complex. A critical review of kratom’s pharmacology and clinical implications published in 2020 and made available at pmc.ncbi.nlm.nih.gov stressed that while high-dose, chronic use can lead to dependence and withdrawal symptoms, the toxicity profile differs from that of classical opioids, and severe adverse events often involve co-ingestion of other drugs or contaminated products.
International health authorities have taken note of both sides of the ledger. In 2021, the World Health Organization’s Expert Committee on Drug Dependence undertook a formal review of kratom, mitragynine and 7-hydroxymitragynine to consider whether they should be placed under international control. After examining the available data, the committee concluded that there was insufficient evidence of significant public health risk to warrant critical review or scheduling and instead recommended that these substances remain under surveillance, a decision summarized on the WHO-focused regulatory news site SupplySide Journal at supplysidesj.com. In other words, the world’s top drug-harm experts explicitly rejected calls for a global ban, opting for monitoring and further research instead.
Some national governments have gone further, shifting from criminalization to a model centered on controlled, culturally informed use. Thailand, which criminalized kratom in the 1940s, removed the plant from its list of controlled narcotics in 2021, effectively decriminalizing cultivation, sale and possession, as explained by regional law firm Tilleke & Gibbins in a detailed briefing at tilleke.com. The reforms came amid broader efforts to modernize narcotics law and to recognize traditional medicinal practices, and they opened the door for regulated kratom products while reducing the burden on the criminal justice system.
In the United States, by contrast, the regulatory map is patchwork. The federal government has not scheduled kratom under the Controlled Substances Act, but several states and municipalities have imposed bans or severe restrictions, often citing the same adverse event reports that federal scientists are now re-examining. Advocates argue that this approach drives consumers toward illicit or poorly labeled products while doing nothing to ensure quality or provide evidence-based guidance on safer use.
One alternative that has gained traction is the “Kratom Consumer Protection Act,” a model law promoted by the American Kratom Association (AKA) that focuses on age limits, labeling and manufacturing standards rather than banning the plant outright. The AKA, a nonprofit advocacy group that has helped block previous federal scheduling attempts, explains on its public education portal at amazingbotanicals.net that its program encourages vendors to adopt good manufacturing practices, test for contaminants and accurately disclose alkaloid content, with the goal of giving consumers a safer, more transparent marketplace.
The logic behind this regulatory path is simple: if kratom is here to stay, as usage surveys suggest, then the primary public health question is not whether it can be eradicated but whether it can be made safer. Data from observational studies reviewed in the 2021 systematic analysis at pmc.ncbi.nlm.nih.gov indicate that many users take kratom specifically to self-manage pain, anxiety or withdrawal from opioids and other substances. For these individuals, forcing the market underground or cutting off access abruptly may not reduce overall risk; instead, it could push them back toward prescription opioids, heroin or synthetic analogues that are far more likely to cause fatal respiratory depression.
Moreover, measured regulation and continued scientific inquiry may be the only viable way to disentangle kratom’s risks from those of the products that currently dominate the market. Without standards, low-cost extracts may contain unpredictable concentrations of 7-hydroxymitragynine, the alkaloid linked to stronger opioid-like effects, or harmful adulterants. Age restrictions, batch testing and clear dosing information—tools taken for granted in other sectors of the supplement and pharmaceutical industries—could reduce the incidence of acute toxicity and give clinicians a clearer picture of what their patients are actually taking, a need underscored by NIDA’s call for better data collection on kratom exposures at nida.nih.gov.
None of this absolves kratom of scrutiny. The same scientific reviews that highlight its therapeutic promise also document dependence and withdrawal in heavy users, the potential for drug interactions and case reports of liver injury. A 2019 perspective on kratom’s impact published in the journal Substance Abuse and archived at pmc.ncbi.nlm.nih.gov emphasized that regular high-dose consumption can lead to compulsive use patterns and that abrupt cessation may produce symptoms reminiscent of, but generally milder than, classical opioid withdrawal. Those are real harms, especially in the absence of medical supervision.
Yet it is precisely because kratom poses non-trivial risks that bans can be counterproductive. Prohibition tends to collapse important distinctions—between leaf and extract, between moderate and heavy use, between traditional preparations and novel formulations—into a single legal status. It can also chill research by making access to standardized plant material more difficult and by stigmatizing participants, hindering the very studies that regulators say they need to craft evidence-based policy. NIDA acknowledges on its kratom page at nida.nih.gov that “much is still unknown” about kratom’s chemistry and health effects, which makes shutting down scientific inquiry at this stage risky.
The WHO’s 2021 decision not to recommend international control offers a template for a more measured path forward: monitor kratom use closely, invest in rigorous, independent studies and tailor national regulations to promote safer products while targeting specific harms. Countries like Thailand, which have shifted from blanket criminalization to regulated acceptance as described at tilleke.com, suggest that it is possible to acknowledge both kratom’s cultural roots and its modern risks without resorting to zero-tolerance policies.
For policymakers grappling with kratom today, the choice is not between an unregulated free-for-all and total prohibition. It is between responding to fear with bans that may drive use into darker corners of the market, or responding to data with a framework that encourages safer use, honest labeling and ongoing scientific scrutiny. As the evidence base grows—from NIH-funded trials to systematic reviews and global health assessments—the case for regulation over prohibition is becoming harder to ignore.
In the end, kratom is neither a miracle cure nor a uniquely malevolent drug. It is a complex plant with a real potential for both benefit and harm, arriving in Western markets at a moment when societies are desperate for new tools to confront pain and addiction. Treating it as an object of study and sensible regulation, rather than as a political prop to be banned or lionized, may be the surest way to protect public health while honoring the lived experiences of the millions of people who already use it.